GW117 induces anxiolytic effects by improving hippocampal functions

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Anxiety disorders are prevalent, necessitating novel therapeutic targets.
• GW117 possesses dual activity as an MT1/MT2 receptor agonist and 5-HT2C receptor antagonist.
• Chronic unpredictable mild stress (CUMS) is a validated model for inducing anxiety-like behaviors.

Purpose of the Study:

• To investigate the anxiolytic effects of GW117 in a CUMS rat model.
• To evaluate the sustained anxiolytic efficacy of GW117 following 21-day administration.
• To elucidate the underlying neurobiological mechanisms of GW117's action.

Main Methods:

• Behavioral assessments including the Novelty-Suppressed Feeding Test (NSFT), Vogel-conflict test, and O-maze test.
• Western blot analysis to quantify protein expression of Bax, cleaved caspase-3, Bcl-2, BDNF, and GFAP.
• BrdU labeling and immunofluorescence staining to assess neuronal regeneration and astrocytogenesis.

Main Results:

• GW117 administration significantly reduced anxiety-like behaviors in the CUMS model.
• Long-term GW117 treatment demonstrated sustained anxiolytic effects.
• GW117 increased hippocampal expression of BDNF, GFAP, and Bcl-2, while decreasing Bax and cleaved caspase-3.
• Elevated populations of BrdU-positive and GFAP-positive cells were observed, indicating enhanced neurogenesis and astrocytogenesis.

Conclusions:

• GW117 exhibits potent and sustained anxiolytic properties.
• The therapeutic effects of GW117 are mediated through the modulation of hippocampal neurogenesis, astrocytogenesis, and apoptosis.
• GW117 represents a promising therapeutic agent for anxiety disorders.